Search alternatives:
significant promise » significant rise (Expand Search), significant progress (Expand Search), significant positive (Expand Search)
promise decrease » point decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
Showing 201 - 220 results of 4,462 for search '(( significant promise decrease ) OR ( significant ((mean decrease) OR (nn decrease)) ))', query time: 0.50s Refine Results
  1. 201
    IFA treatment facilitated host immune clearance of hypervirulent <i>K</i>. <i>pneumoniae</i> by targeting capsule.

    IFA treatment facilitated host immune clearance of hypervirulent <i>K</i>. <i>pneumoniae</i> by targeting capsule. by Tingting Wang (123983)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 202
    IFA effectively limited bacterial dissemination and protected mice from lethal hypervirulent <i>K</i>. <i>pneumoniae</i> pneumonia.

    IFA effectively limited bacterial dissemination and protected mice from lethal hypervirulent <i>K</i>. <i>pneumoniae</i> pneumonia. by Tingting Wang (123983)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 203
    IFA reduced the virulence of hypervirulent <i>K</i>. <i>pneumoniae</i> in <i>G</i>. <i>mellonella</i> larvae.

    IFA reduced the virulence of hypervirulent <i>K</i>. <i>pneumoniae</i> in <i>G</i>. <i>mellonella</i> larvae. by Tingting Wang (123983)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 204
    IFA reduced the capsular biosynthesis through altering bacterial metabolism.

    IFA reduced the capsular biosynthesis through altering bacterial metabolism. by Tingting Wang (123983)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 205
    IFA effectively reduced the production of <i>K</i>. <i>pneumoniae</i> capsule.

    IFA effectively reduced the production of <i>K</i>. <i>pneumoniae</i> capsule. by Tingting Wang (123983)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 206
    IFA disarmed capsule-mediated immune evasion.

    IFA disarmed capsule-mediated immune evasion. by Tingting Wang (123983)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 207
    IFA abrogated capsule-associated hypermucoviscosity phenotypes of hypervirulent <i>K</i>. <i>pneumoniae</i>.

    IFA abrogated capsule-associated hypermucoviscosity phenotypes of hypervirulent <i>K</i>. <i>pneumoniae</i>. by Tingting Wang (123983)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 208
    IFA sensitized hypervirulent <i>K</i>. <i>pneumoniae</i> to complement-mediated killing by inhibiting capsule.

    IFA sensitized hypervirulent <i>K</i>. <i>pneumoniae</i> to complement-mediated killing by inhibiting capsule. by Tingting Wang (123983)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 209
    Validation of distinct contribution of capsule and hypercapsule-associated HMV in IFA-conferred protection against hvKP infection using a <i>ΔrmpD</i>-K7 mutant.

    Validation of distinct contribution of capsule and hypercapsule-associated HMV in IFA-conferred protection against hvKP infection using a <i>ΔrmpD</i>-K7 mutant. by Tingting Wang (123983)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 210
    Maximum likelihood estimates of trans-log mean stochastic function.

    Maximum likelihood estimates of trans-log mean stochastic function. by James Anaba Akolgo (14129379)

    Published 2025
    Save to List
    Saved in:
  11. 211
    Irradiation effect on <i>D. melanogaster</i> male sterility.

    Irradiation effect on <i>D. melanogaster</i> male sterility. by Flavia Cerasti (21655934)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 212
    Growth characteristics of <i>A. baumannii</i> strains used in this study.

    Growth characteristics of <i>A. baumannii</i> strains used in this study. by Techit Thavorasak (13138440)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 213
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 214
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 215
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 216
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 217
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 218
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 219
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 220
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: